Tech Company Financing Transactions
Mabylon AG Funding Round
Private investors participated in a $37 million venture round for Mabylon AG. The funding round was announced on 8/12/2025.
Transaction Overview
Company Name
Announced On
8/12/2025
Transaction Type
Venture Equity
Amount
$37,000,000
Round
Undisclosed
Investors
Proceeds Purpose
The company intends to use the funds to advance its lead program MY006, a tri-specific antibody neutralizing peanut allergens, to completion of a Phase Ia/b trial in 2027 with the goal to generate robust safety and preliminary efficacy data.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Wagistrasse 14
Schlieren, 8952
Switzerland
Schlieren, 8952
Switzerland
Phone
Website
Email Address
Overview
Mabylon AG is a Swiss biotechnology company leveraging its technology platform and unique know-how to discover and engineer novel antibody therapeutics in allergy, inflammation and neurology. The firm's strength stems from extensive and successful experiences in both the pharmaceutical and biotech industries. Mabylon's drug discovery goal is to rapidly create high-quality antibody libraries against validated targets from which the best functional, therapeutically relevant products are selected. To this aim, Mabylon has access to diverse sources of immune repertoires, focusing on patients with relevant conditions.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Alcide Barberis
Browse more venture capital transactions:
Prev: 8/12/2025: Gameto venture capital transaction
Next: 8/13/2025: NeoLogic venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on all VC transactions involving tech companies. VC investment data records reported here come from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs